Boston, Massachusetts--(Newsfile Corp. - September 25, 2023) - hC Bioscience has appointed Jose Lora, Ph.D., as its Chief Scientific Officer (CSO). In this position, Lora will play a pivotal role in helping to shape the Company's strategic direction around its innovative portfolio of therapeutic tRNAs and advancing their lead candidates into the clinic..

马萨诸塞州波士顿-（Newsfile Corp.-2023年9月25日）-hC Bioscience已任命Jose Lora博士为其首席科学官（CSO）。在这个职位上，Lora将在帮助塑造公司围绕其创新性治疗性tRNA组合的战略方向以及将其主要候选人推向临床方面发挥关键作用。。

To view the full announcement, including downloadable images, bios, and more, click here.

要查看完整的公告，包括可下载的图像，生物学等，请单击此处。

Key Takeaways:

主要优点：

hC Bioscience has appointed Jose Lora, Ph.D., as its new Chief Scientific Officer.

hC Bioscience已任命Jose Lora博士为其新的首席科学官。

Lora's expertise will help shape hC Bioscience's research and development strategies with an initial focus on bringing the Company's lead candidate for the treatment of cancer into the clinic.

Lora的专业知识将有助于塑造hC Bioscience的研发战略，最初的重点是将公司的癌症治疗领先候选人带入临床。

In addition, Lora will oversee the management of the Company's development pipeline, prioritizing therapeutic applications, and expanding the platform to address additional types of mutations.

此外，Lora将监督公司开发流程的管理，优先考虑治疗应用，并扩展平台以解决其他类型的突变。

Click image above to view full announcement.

点击上面的图片查看完整的公告。

About hC Bioscience

关于hC生物科学

hC Bioscience is dedicated to bringing tRNA-based therapies to patients. Therapeutic tRNA is a new class of treatments that target disease-causing proteins at the level of translation.

hC Bioscience致力于为患者提供基于tRNA的疗法。治疗性tRNA是一类新的治疗方法，可在翻译水平上靶向致病蛋白。

Our initial focus is designing and developing therapeutic tRNAs to treat cancers caused by gene mutations and inherited diseases. Our lead indications include colorectal cancer that has metastasized to the liver (CRCLM), inherited retinal disease such as retinitis pigmentosa, and muscular dystrophies. .

我们最初的重点是设计和开发治疗性tRNA，以治疗由基因突变和遗传性疾病引起的癌症。我们的主要适应症包括已转移至肝脏的大肠癌（CRCLM），遗传性视网膜疾病（如色素性视网膜炎）和肌肉营养不良。 .

Therapeutic tRNA represents the next-generation of RNA-based therapies. It holds the potential to repair or eliminate damaged proteins from the body by modifying errors in mRNA, a key molecule that translates genes into proteins.

治疗性tRNA代表下一代基于RNA的疗法。它具有通过修饰mRNA中的错误来修复或消除体内受损蛋白质的潜力，mRNA是将基因转化为蛋白质的关键分子。

hC Bioscience is Based in Boston, MA and was founded on technology out of Universities such as Iowa, Wisconsin, Rochester, and Chicago. The Company secured $40 million in series A financing with investments from leading venture firms including ARCH Ventures, Takeda Ventures, 8VC, Taiho Ventures, Panacea Venture, and CureDuchene..

hC Bioscience位于马萨诸塞州波士顿，成立于爱荷华州，威斯康星州，罗切斯特和芝加哥等大学以外的技术。该公司通过包括ARCH Ventures，Takeda Ventures，8VC，Taiho Ventures，Panacea venture和CureDuchene在内的领先风险公司的投资，获得了4000万美元的A系列融资。。

Contacts:

联络：

Savannah Beaver

萨凡纳海狸

(617) 804-0366

(617) 804-0366

savannah@reportablenews.com

savannah@reportablenews.com

Source: hC Bioscience

来源：hC Bioscience

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/181787

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/181787